Piper Sandler analyst Adam Maeder raised the firm’s price target on Inari Medical (NARI) to $52 from $50 and keeps a Neutral rating on the shares. The firm notes Inari reported record high revenue in Q3 with $153.4M, which topped both consensus and its model. Piper was encouraged to see that the beat was driven by the company’s U.S. core VTE franchise.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NARI: